This phase III study compared SB3, a trastuzumab (TRZ) biosimilar, with reference TRZ in patients with human epidermal growth factor receptor 2-positive early breast cancer in the neoadjuvant setting (ClinicalTrials.gov identifier: NCT02149524).
INTRODUCTION
The introduction of trastuzumab (TRZ; Herceptin; Genentech, South San Francisco, CA) into the therapeutic armamentarium for human epidermal growth factor receptor 2 (HER2)-positive breast cancer has dramatically changed the natural history of this disease. [1] [2] [3] [4] [5] [6] [7] [8] However, biotherapies are expensive and not readily available in some countries. As a result, economical biosimilars may increase patient access to critical therapies in some areas and save costs, thereby facilitating the availability of resources for innovative biotherapies in other countries.
and mediating antibody-dependent cellular cytotoxicity against such tumor cells in vitro. In healthy patients, pharmacokinetic (PK) equivalence was demonstrated between SB3 and European Unionsourced TRZ or US-sourced TRZ. 10 The primary objective of the current study was to demonstrate the equivalent clinical efficacy of SB3 and TRZ in terms of the pathologic complete response in the primary breast tumor (bpCR) for women with HER2-positive early breast cancer treated with a neoadjuvant strategy.
PATIENTS AND METHODS
This study was conducted in compliance with the International Council for Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. The study was reviewed and approved by an independent ethics committee or institutional review board. Written informed consent was obtained from all patients before any study-related procedures were performed.
Patients
Eligibility criteria included the following: age 18 to 65 years; Eastern Cooperative Oncology Group performance status of 0 to 1; nonmetastatic, unilateral stage II to III primary breast cancer, including inflammatory breast cancer, with tumor size $ 2 cm; and histologically confirmed primary invasive adenocarcinoma of the breast, with HER2 positivity confirmed by a central laboratory or an accredited local laboratory. 11 Other inclusion criteria included known estrogen receptor (ER) and progesterone receptor (PR) status and baseline left ventricular ejection fraction (LVEF) $ 55% measured by echocardiography or multigated acquisition scan. Sentinel node biopsy before initiation of neoadjuvant therapy could be undertaken. A list of exclusion criteria can be found in the Data Supplement.
Study Design and Treatment
This was a phase III, randomized, double-blind, parallel-group, multicenter study (ClinicalTrials.gov identifier: NCT02149524; EudraCT No.: 2013-004172-35) . Random assignment was stratified by breast cancer type (operable v locally advanced) and hormone receptor status (ER and/or PR positive v ER and PR negative). A block stratified randomization method was used with dynamic block allocation by country. Patients were randomly assigned (1:1) to receive either SB3 or European Union-sourced TRZ intravenously every 3 weeks in a neoadjuvant setting for eight cycles concurrently with eight cycles of chemotherapy (Fig 1) . Study drugs were administered at a loading dose of 8 mg/kg and at 6 mg/kg for subsequent cycles. Chemotherapy consisted of docetaxel 75 mg/m 2 for four cycles followed by four cycles of fluorouracil 500 mg/m 2 , epirubicin 75 mg/m 2 , and cyclophosphamide 500 mg/m 2 . Patients subsequently underwent surgery, followed by an additional 10 cycles of adjuvant treatment with SB3 or TRZ, as per random assignment, to complete 1 year of treatment. Radiotherapy was administered per local practice, as was adjuvant hormonal therapy.
Study End Points
Efficacy. The primary end point was the bpCR rate, which was defined as no histologic evidence of residual invasive tumor cells in the breast.
12 Pathologic response was assessed by the local pathologist. For quality control, all bpCRs were reviewed by the study pathologist board. Secondary end points included total pathologic complete response (tpCR) rate, defined as no residual invasive tumor cells in breast and axillary lymph nodes; overall response rate (ORR); and event-free survival and overall survival, which were measured from the date of random assignment.
Safety. Treatment-emergent adverse events (TEAEs) were monitored throughout the study. Prespecified TEAEs of special interest included infusion-related reactions, congestive heart failure (CHF), and asymptomatic left ventricular systolic dysfunction. The severity of TEAEs was classified by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0, with the exception of CHF (graded according to NCI-CTCAE v4.0 and the New York Heart Association functional classification) and asymptomatic left ventricular systolic dysfunction (graded according to NCI-CTCAE v3.0). LVEF was assessed every four cycles of study treatment. This report includes safety results during the neoadjuvant treatment period.
PK. Blood samples were collected for determination of the predose concentrations (C trough ) at cycles 1, 3, 5, 7 , and 8 using a validated enzymelinked immunosorbent assay. WinNonlin v5.2 (Pharsight, Mountain View, CA) was used for data collection and management.
Immunogenicity. Immunogenicity testing was performed to search for antidrug antibodies (ADAs) and neutralizing antibodies against SB3 or TRZ. Blood samples were collected before drug administration in cycles 1, 5, 9, and 14, and 30 days after the last dose of study drug and analyzed using the Meso Scale Discovery platform (Rockville, MD). An overall ADA result was defined as positive for a patient with treatment-induced or treatmentboosted ADA, as defined in the Data Supplement.
Statistical Analyses
The primary analysis was conducted according to protocol amendment (April 2015) using the per-protocol set (PPS), which was defined as all patients in the full analysis set (FAS) who completed eight cycles of neoadjuvant therapy and surgery without prespecified major protocol deviations. On the basis of a statistical analysis plan that was finalized before unblinding of the study database, 90% CI of the ratio in the bpCR rate was secondarily considered in assessing the primary efficacy. The FAS consisted of all patients who were randomly assigned at the random assignment visit.
Equivalence was declared if the 95% CI of the ratio in the bpCR rate between arms was contained within the predefined margin of 0.785 to 1.546 or if the 95% CI of the difference in the bpCR rate between treatments was contained within the predefined margin of 6 13%. The equivalence margin of 0.785 to 1.546 was based on a meta-analysis of three neoadjuvant studies in which patients were randomly assigned to receive TRZ or non-TRZ treatment and had bpCR results available. 1, 13, 14 In the meta-analysis, the ratio of the bpCR rates of TRZ to non-TRZ treatment was 2.07, with a 90% CI of 1.546 to 2.795. The lower equivalence margin in the current study preserved approximately 50% of the TRZ treatment effect over placebo, and the upper equivalence margin was taken from the lower limit of the 90% CI of the ratio.
With an expected bpCR rate of 37.5%, 358 patients per arm were considered evaluable to meet 80% power to detect the equivalence. Considering the nonevaluable patients, 806 patients were to be randomly assigned, incorporating an 11% loss from the primary efficacy analysis. The primary efficacy analysis used a stratified Cochran-Mantel-Haenszel test, with hormone receptor status, breast cancer type, and region as factors to obtain the CI.
To assess the robustness of the main results, the following supplementary analyses were planned: bpCR using log-linked binomial model, available patient analysis and nonresponder imputed analysis in the FAS, and tpCR comparison in the PPS and nonresponder imputed analysis in the FAS.
Patient demographic and baseline clinical characteristics were compared between the two arms using the x 2 test or F test as appropriate. Safety and immunogenicity data were summarized using descriptive statistics in the safety set, consisting of patients receiving at least one dose of either study drug. PK analysis was performed in all patients who had one or more C trough result. Statistical analysis of the log e -transformed C trough at predose cycle 8 was performed using an analysis of variance model. Equivalence in C trough was concluded if the 90% CI for the ratio of geometric means of SB3 to TRZ was within the acceptance interval of 80% to 125%. Statistical analyses were performed using SAS v9.2 (SAS, Cary, NC).
RESULTS

Patients and Exposure
Between April 2014 and August 2015, 875 patients were randomly assigned to receive either SB3 (n = 437) or TRZ (n = 438) across 97 study centers (Fig 2) . A total of 800 patients (SB3, n = 402; TRZ, n = 398) completed neoadjuvant therapy and surgery, representative of the PPS population. Demographics and baseline disease characteristics in the FAS population were well balanced, with no statistical differences between the two arms (Table 1) . Overall, the median age was 51 years (range, 22 to 65 years). The majority of patients had T2 disease (52.8%) and clinically involved lymph nodes (79.5%). ER and PR were negative in 40.9% of At the time of data cutoff, the median follow-up durations were 337 days (range, 94 to 489 days) and 338 days (range, 24 to 475 days) in the SB3 and TRZ arms, respectively. There were no relevant differences between the two arms in the mean values for the relative dose-intensity of both investigational products and noninvestigational products (Table 2) .
Efficacy
All bpCRs assessed by the local pathologist were reviewed and confirmed by the study pathologist board, with one instance of disparity observed of the bpCR result that was recorded after the local pathologist report. In the PPS, the proportions of patients achieving bpCR were 51.7% (208 of 402 patients) in the SB3 group and 42.0% (167 of 398 patients) in the TRZ group (Table 3 ). The adjusted ratio of bpCR was 1.259 (95% CI, 1.085 to 1.460), which was within the predefined equivalence margins. The adjusted difference was 10.70% (95% CI, 4.13% to 17.26%), with the lower margin contained within and the upper margin outside the predefined equivalence margins.
In the FAS, bpCR rates were 49.0% (214 of 437 patients) and 39.7% (174 of 438 patients) for the SB3 and TRZ arms, respectively. The adjusted ratio of the bpCR rate was 1.243 (95% CI, 1.070 to 1.444), and the adjusted difference in the bpCR rate was 9.59% (95% CI, 3.26% to 15.91%). In the PPS, tpCR rates were 45.8% and 35.8% for the SB3 and TRZ arms, respectively. The bpCR and tpCR results in the FAS were similar to those seen in the PPS.
The bpCR rates were higher in ER-and PR-negative patients than in ER-and/or PR-positive patients (Data Supplement). All complementary sensitivity analyses are presented in Table 3 . Eventfree survival and overall survival data were not sufficiently mature for analysis at the time of the data cutoff date.
Safety
During the neoadjuvant period, TEAEs were reported in 96.6% of patients (422 of 437 patients) in the SB3 group and 95.2% of patients (417 of 438 patients) in the TRZ group (Table 4) . The most common TEAEs were neutropenia, alopecia, nausea, and leukopenia. TEAEs resulted in the death of four patients (one suicide in the SB3 group and one death each as a result of myocardial infarction, sudden death, and pulmonary embolism in the TRZ group); none of these events were considered to be related to study drug. The incidence of TEAEs of special interest was similar between the arms. Two patients in the SB3 group presented with CHF. The first patient, with a history of hypertension and diabetes, had the event reported at cycle 5 and recovered from the event 11 days later. The second patient had the event reported at cycle 6 and recovered 11 days later.
PK
The PK population included 161 and 152 patients in the SB3 and TRZ arms, respectively. Mean C trough profiles from cycle 3 to cycle 8 were similar between the two treatment groups. A total of 99.2% of patients in the SB3 group and 97.3% of patients in the TRZ group had C trough values . 20 mg/mL at predose cycle 8. At cycle 8, the geometric least squares mean ratio of C trough was 110% (52.535 mg/mL and 47.816 mg/mL in the SB3 and TRZ groups, respectively), and the 90% CI was 102% to 119%, which was contained within the predefined equivalence margins.
Immunogenicity
Up to cycle 9, positive ADA results were reported for three patients (0.7%) in the SB3 group and zero patients (0.0%) in the TRZ group. One of three patients obtained bpCR; none of these three patients presented significant TEAEs related to immunogenicity, such as infusion-related reaction. The overall incidence of ADAs was too low to perform a statistical analysis of the relationship between the ADA status and efficacy or safety, but there was no significant difference between patients who were ADA positive and negative.
DISCUSSION
Evaluation of a biosimilar is based on the totality of evidence, 15, 16 including the rudimental comparative analytical and functional characterization studies with the supportive nonclinical and clinical studies. The aim of the clinical development of a biosimilar, according to this guiding principle, is to compare its efficacy and safety with the reference product, not to determine patient benefit per se. 15, 17 A neoadjuvant setting in early breast cancer, compared with a metastatic setting, was chosen because it is a more sensitive and homogenous group with fewer confounding factors influencing the evaluation. 15, 17, 18 Although controversy still exists regarding whether pathologic complete response (pCR) is a valid surrogate end point related to event-free and overall survival, the primary efficacy evaluation on the basis of the pCR criterion has been acknowledged in HER2-positive breast cancer trials, such as the HannaH and NeoSphere studies. [19] [20] [21] [22] [23] [24] In our study, bpCR was selected as the primary end point rather than tpCR to eliminate confounding factors in determining the pCR rate. Axillary lymph node assessments can affect tpCR results depending on the timing of the axillary staging, the techniques of the sentinel lymph node biopsy, and the extent of the axillary dissection. 25 Because these factors are not attributable to actual differences between drugs, bpCR seems to be the most stringent criterion with limited confounding factors. Neoadjuvant chemotherapy was chosen to achieve maximum efficacy with acceptable tolerability and was determined to be TRZ with concomitant administration of a taxane followed by an anthracycline. 13, 26 In the HannaH study, the same chemotherapy was used to compare intravenous and subcutaneous TRZ. The results did not show significant safety concerns and led to subcutaneous TRZ Abbreviations: bpCR, breast pathologic complete response; ORR, overall response rate; SB3, trastuzumab biosimilar; tpCR, total pathologic complete response; TRZ, reference trastuzumab. *Secondary analysis conducted based on a statistical analysis plan that was finalized before data unblinding. †For nonresponder imputed analysis, patients with missing assessments were considered to be nonresponders. approval. A randomized phase III trial (Z1041) evaluated the effect of the timing of TRZ administration with anthracycline and taxane neoadjuvant chemotherapy. 27 Although the study did not demonstrate added benefit with concomitant administration of anthracycline and TRZ, there were no additional safety concerns. Furthermore, a dose of docetaxel 75 mg/m 2 was used in our study to increase tolerability on the basis of a study in metastatic breast cancer, 28 despite that docetaxel 100 mg/m 2 is considered the standard dose for monotherapy. The progression and survival results were comparable with doses of 60, 75, and 100 mg/m 2 , whereas the rates of neutropenia, febrile neutropenia, and infection were notably decreased when the docetaxel dose was reduced from 100 to 75 mg/m 2 . Both ratio (relative risk) and absolute difference were used to assess the primary efficacy end point. Although both metrics are valid methods for assessment, the ratio metric provides a better adjustment to the lower event rate in a noninferiority or an equivalence study. 29 The CI of the ratio in the bpCR rates was compared using a predefined asymmetric equivalence margin. An asymmetric interval for the primary efficacy end point is possible when the drug (TRZ) dose level used in the clinical study is near the plateau of the dose-response curve with the unlikelihood of dose-related toxicity, considering that the rest of the results from all other end points, such as efficacy, safety, and immunogenicity, are similar between arms.
15
Overall, neoadjuvant TRZ has been administered in combination with different chemotherapy regimens, resulting in pCR rates ranging from 26% to 65%. 30 The bpCR rates observed in this study (51.7% and 42.0% in the SB3 and TRZ groups, respectively) are within the ranges previously reported in the literature and close to results reported in studies with similar chemotherapy regimens (concomitant administration of TRZ with taxanes and anthracyclines). In the HannaH study, the corresponding rates were 40.7% with intravenous TRZ and 45.4% with subcutaneous TRZ. 22 In the Z1041 study, bpCR rates were 56.5% and 54.2% in the sequential and concurrent TRZ neoadjuvant chemotherapy groups, respectively.
27
The observed bpCR rates demonstrated equivalence between SB3 and TRZ on the basis of the ratio of bpCR rates, with the bpCR rate of the SB3 group numerically 10% higher than that of the TRZ group. Patient demographic and baseline disease characteristics were well balanced between arms; therefore, the difference observed in bpCR rates is difficult to explain. Among numerous lots of TRZ that have been analyzed for physicochemical and biologic properties for . 5 years, certain lots showed a marked downward drift in the level of glycosylation, FcgRIIIa binding activities, and antibody-dependent cell-mediated cytotoxicity activities. Because some of these lots were used as a reference drug in this clinical study, it cannot be excluded that the shifts of these quality attributes in the reference drug did not have an impact on the presented results. 31 The physicochemical and biologic properties of the SB3 lots used for the clinical study were also intensively analyzed and have demonstrated similarity to predrifted TRZ lots.
The safety profiles of SB3 and TRZ during the neoadjuvant treatment period were similar. The TEAEs were as expected for this study population and for this anticancer regimen. Immunogenicity was markedly low in both treatment groups. Patients who were ADA positive did not show a significant difference in efficacy and safety results compared with patients who were ADA negative, even though the relationship between immunogenicity and treatment efficacy and safety could not be statistically analyzed.
A comprehensive evaluation of the full data, including similarity in clinical efficacy, safety, PK, and immunogenicity of the proposed biosimilar and the reference drug, is recommended. 15, 17 In conclusion, this study demonstrated similarity between SB3 and TRZ. Patients may continue in a long-term extension study (ClinicalTrials.gov identifier: NCT02771795) that will further monitor safety, event-free survival, and overall survival.
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